Fig. 4From: Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysisForest plot of cardiovascular adverse events: risk difference of TG versus UCBack to article page